# Insecticides India share price today (Insecticides India Ltd, NSE: INSECTICID)

> Insecticides India share price today: ₹555.15 at the NSE close on 3 November 2026, down 23.1% in a year. Insecticides India (NSE: INSECTICID) is worth ₹1,616 crore, trades at a P/E of 12.9 and has closed between ₹519.20 and ₹748.95 over the past 52 weeks. > Insecticides India Ltd's P/E is near the low end of its own history, higher than only 28% of past readings, and its quarterly results are still getting worse. INSECTICID · Pesticides/Agrochemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/insecticides-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹555.15 (−23.1% in a year)
- P/E: 12.9× (lower than 72% of the last 10 years)
- Revenue (Jun 2026): ₹612 Cr (−11.4% on a year ago)
- Profit (Jun 2026): ₹44.0 Cr (−24.1% on a year ago)
- Operating margin: 11.0% (−1.0 points on a year ago)
- ROCE: 16%, FY26
- ROIC: 11.2%, against a 12.0% cost of capital: −0.8 points

The main question: the P/E is near the low end of its own history, higher than only 28% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. ## What is the Insecticides India share price today? Insecticides India Ltd's share price was ₹555.15 at the close on 3 November 2026. It has been falling for 14 weeks. That is 13.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹519 and ₹749, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 22 weeks running. Over the last 11 years the share price moved +159% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 19 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Insecticides India this quarter? Two changes stood out: revenue fell in the June 2026 quarter and profit down on a year earlier for 4 quarters in a row. 1. Revenue fell in the June 2026 quarter Revenue was ₹612 crore, -11.4% on a year earlier (₹691 crore), after 5 quarters of growth. Why: Revenue fell because erratic monsoon and drought pockets hurt demand, and weak sentiment made the industry cautious. Next results: check whether Q2 revenue turns positive after the weather disruption. From the earnings call on 28 Sep 2026. 2. Profit down on a year earlier for 4 quarters in a row In the June 2026 quarter profit was ₹44 crore, -24.1% on a year earlier. Why: Profit fell because sales were lower while many costs stayed fixed, so the revenue drop hit earnings harder. Next results: check whether the full-year margin stays above last year as more sales cover fixed costs. From the earnings call on 28 Sep 2026. ## What are Insecticides India's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Insecticides India reported revenue of ₹612 crore, down 11.4% from ₹691 crore a year earlier, and a profit of ₹44.0 crore, down 24.1% from ₹58.0 crore. ### Insecticides India results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹612 crore | ₹691 crore | −11.4% |
| Profit | ₹44.0 crore | ₹58.0 crore | −24.1% |
| Earnings per share | ₹15.08 | ₹19.97 | −24.5% |
| Operating margin | 11.0% | 12.0% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Insecticides India's management discussed these results on a call held on 28 September 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Insecticides India share price history? Insecticides India closed at ₹555.15 on 3 November 2026, down 23.1% from ₹722.25 a year earlier (31 October 2025) and up 24.7% over five years. Its highest weekly close since March 2016 was ₹1,046.30 on 25 July 2025. ### Insecticides India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹520.10 | +6.7% |
| 1 month ago · 1 Oct 2026 | ₹568.70 | −2.4% |
| 6 months ago · 30 Apr 2026 | ₹701.45 | −20.9% |
| 1 year ago · 31 Oct 2025 | ₹722.25 | −23.1% |
| 3 years ago · 3 Nov 2023 | ₹520.30 | +6.7% |
| 5 years ago · 4 Nov 2021 | ₹445.13 | +24.7% |
| 10 years ago · 4 Nov 2016 | ₹327.73 | +69.4% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹214.63 | +158.7% |
| Highest weekly close since March 2016 · 25 Jul 2025 | ₹1,046.30 | −46.9% |
| Lowest weekly close since March 2016 · 20 Mar 2020 | ₹191.07 | +190.5% |
| 52-week high (weekly close) · 22 May 2026 | ₹748.95 | −25.9% |
| 52-week low (weekly close) · 30 Oct 2026 | ₹519.20 | +6.9% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Insecticides India? 3 Nov 2026: Insecticides India closed at ₹555.15, up 6.7% on the week and down 2.4% on the month. 28 Sep 2026: Insecticides India held its results call for April to June 2026. Management guided: Q2 expected positive on a year earlier and H2 expected to recover first-half industry losses. ### Earlier

- Results for April to June 2026: Revenue down 11.4% and profit down 24.1% on a year earlier. - 6 Feb 2026: ex-date for an interim dividend of ₹2 a share. ## What dividend does Insecticides India pay? Insecticides India paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.36% at the ₹555.15 close on 3 November 2026. The last was an interim dividend of ₹2 a share, ex-date 6 February 2026. ### Insecticides India dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 6 Feb 2026 | ₹2 | Interim |
| 23 Aug 2024 | ₹2 | Interim |
| 10 Nov 2023 | ₹3 | Interim |
| 24 Feb 2023 | ₹3 | Interim |
| 15 Sep 2022 | ₹3 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Insecticides India Ltd paid out 4% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Insecticides India management say on the latest results call? On the call for April to June 2026, held on 28 September 2026, Insecticides India's management guided: Q2 expected positive on a year earlier and H2 expected to recover first-half industry losses. > “Percentage-wise, I think it should be better than last year. It may not be significantly higher, but it should not be lower than last year.”
> Sandeep Agarwal, CFO, on the call for April to June 2026

### What management guided

- Dahej capacity expected to be fully utilized in the coming year; existing formulation capacity already full. - Insecticide sales returns expected at approximately 50% of last year's level. - Full-year operating margin should be better than last year, though not significantly higher. - KAEROS turnover expected at ₹100 crore this year. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/4734-28-Sep-2026.pdf). (From the call for April to June 2026, 28 September 2026.)

## What to watch in Insecticides India's next results? When Insecticides India reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 revenue to turn positive on a year earlier after weather disruption - check the next results packet. - What to check (from the call)
- Q2 revenue to turn positive on a year earlier after weather disruption - check the next results packet. - Second-half recovery to offset first-half weakness - check sales, volumes and regional rainfall effects. - Sales returns to remain near the indicated level and inventory to decline - check Q2 disclosures. - Full-year operating margin to stay above last year through turnover absorption - check reported margin. ## Which stock lists is Insecticides India on? Insecticides India is on one of our India lists: 52 week high & low. [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)

## Is Insecticides India profitable? Insecticides India Ltd earned ₹44.0 Cr of net profit in the Jun 2026 quarter, −24.1% on the same quarter a year earlier. Full-year FY26 profit was ₹139 Cr. Over 10 years profit has grown 13.3% a year on average. That is 7.2% of the quarter's revenue. The same quarter a year earlier earned ₹58.0 Cr. For the full year, FY26 profit was ₹139 Cr (−2.1% on the year before). Why profit moved: revenue changed −11.4% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −20.7% and revenue +4.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Insecticides India make, and is it growing? Insecticides India Ltd reported ₹612 Cr of revenue in the Jun 2026 quarter, −11.4% on the same quarter a year earlier. Over 10 years it has grown 9.0% a year on average. The last full year, FY26, came in at ₹2,140 Cr. The last four reported quarters add to ₹2,061 Cr. FY26 revenue was ₹2,140 Cr, +7.0% on the year before. Recent pace: the last four quarters grew +4.2% on average, against 9.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.3%, against +1.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −16.7%, against +1.2% a year (rolling over). ## How much of every ₹100 of sales does Insecticides India keep? Insecticides India Ltd's operating margin was 11.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 7.0% and 16.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.2 percentage points on the year while gross margin changed +2.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Insecticides India's profit turning into cash? Over the last 3 years, 99% of Insecticides India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹100 Cr of operating cash against ₹139 Cr of profit. After ₹93.0 Cr of spending on assets, ₹7.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 99% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.2× depreciation over three years. The next section checks what that spending is building. ## Where does Insecticides India's cash go? Insecticides India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 177 days in FY26, down from 177 days in FY21. It spent ₹208 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 215 days on average. At FY26 sales of ₹2,140 Cr, each day of that cycle ties up about ₹5.9 Cr, so roughly ₹1,038 Cr is tied up in the business at any time. FY26: customers took 83 days to pay and stock sat for 215 days, about 7.1 months of sales sitting as stock, for a full cycle of 177 days, shorter than FY21's 177. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 215 days. Customers pay about 83 days after that. Suppliers are paid at 121 days. Together that makes the 177-day cycle. Spending on assets: ₹208 Cr over the last 3 years, against ₹94.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹130 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Insecticides India's P/E ratio, and how does it compare with its own history? Insecticides India Ltd's P/E is 12.9×, near the low end of its own history: it has been lower only 28% of the time. Its usual P/E (the middle reading) is 15.1×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −1.8% while the price moved −23.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +4.5% a year; about +4.0% a year came from earnings growth and about +0.5 percentage points from the multiple (roughly no change); over 10 years the price moved +5.4% a year; about +12.8% a year came from earnings growth and about −7.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Insecticides India business getting better or worse? Insecticides India Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +109.7% at its peak to −16.7% now), while ROCE is still 15.6%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Insecticides India earn on its capital? Insecticides India Ltd earned a ROCE of 16% in FY26. That is up from a low of 10% in FY23. Its return on capital used (ROIC) is 0.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 6.5% net margin and 1.07× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.5% net margin × 1.07× asset turnover × 1.64× leverage (assets divided by equity) ≈ 11.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 11.2% − 12.0% = −0.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 11.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Insecticides India have too much debt? Insecticides India Ltd has total debt of ₹157 Cr against shareholder equity of ₹1,220 Cr as of Jun 2026, so its debt is 0.13× its equity, which is very little. Year by year, that ratio went from 0.06 in FY22 to 0.13 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Insecticides India shareholding pattern? Foreign institutions cut their stake in Insecticides India Ltd by 1.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 4.4% of the company. Domestic institutions moved +0.2 points over the same period, to 9.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −1.0 points over 8 quarters, to 4.4%; Domestic institutions: +0.2 points over 8 quarters, to 9.3%; Promoters: +0.1 points over 8 quarters, to 72.3%. Why the owners changed: foreign institutions drove it (−1.0 points). They reduced their stake. ## How far is Insecticides India from balance-sheet trouble? For Insecticides India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Insecticides India rank in its industry? 40.5 out of 100, rank 22 of 25 in Pesticides/Agrochemicals, with 96% of the evidence available. Insecticides India Ltd scores 40.5 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 22. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 9.2 + 12.5 + 10.6 + 8.2 = 40.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Insecticides India compared with? Insecticides India ranks 22 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 40.5 out of 100. 1. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 71.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.5/25 · ROCE 30.2% · Operating margin 16% · 100% evidence Valuation 19.2/20 · P/E 9.3× · PEG 0.3 · 100% evidence Relative strength 4.6/20 · Lead over its industry -14.3% · Lead over NIFTY 500 -22.1% · 1 year -23.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.5 + 19.5 + 19.2 + 4.6 = 71.8 · What this means: Earnings are strong; relative strength in its sector is -14.3% and the one-year return is -23.1%. 2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) turning · Most evidence points up · 83% evidence 70.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 2 points · 83% evidence Capital efficiency 20.2/25 · ROCE 22.8% · Operating margin 21% · 95% evidence Valuation 5.4/20 · P/E 51.8× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 38.3% · Lead over NIFTY 500 25.1% · 1 year 101.5% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.1 + 20.2 + 5.4 + 16.7 = 70.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 81% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue -2.8% · Profit 23.8% · Operating margin change 2 points · 88% evidence Capital efficiency 19.6/25 · ROCE 29.1% · Operating margin 20% · 100% evidence Valuation 13.4/20 · P/E 20× · PEG 1.28 · 100% evidence Relative strength 8.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -20.8% · 1 year -33.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 19.6 + 13.4 + 8.6 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 81% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 8.2% · Profit 43.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.6/25 · ROCE 18.6% · Operating margin 12% · 100% evidence Valuation 15.9/20 · P/E 17.4× · PEG 0.33 · 100% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -9.4% · 1 year -36.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 24.3 + 13.6 + 15.9 + 9.8 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · losing its lead · Evidence leans up · 81% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 8.7% · Profit 13.2% · Operating margin change 1 points · 88% evidence Capital efficiency 14.7/25 · ROCE 16.8% · Operating margin 15% · 100% evidence Valuation 17.5/20 · P/E 14.3× · PEG 0.38 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.7% · 1 year -9.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 14.7 + 17.5 + 12.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans up · 81% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 17% · Profit 10.1% · Operating margin change -2 points · 88% evidence Capital efficiency 15.4/25 · ROCE 16.6% · Operating margin 14% · 100% evidence Valuation 18.2/20 · P/E 12× · PEG 0.36 · 100% evidence Relative strength 8.2/20 · Lead over its industry n/a · Lead over NIFTY 500 -23% · 1 year -40.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 15.4 + 18.2 + 8.2 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · breaking out · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 48.4% · Profit 81.5% · Operating margin change 1 points · 88% evidence Capital efficiency 14.1/25 · ROCE 19.6% · Operating margin 11% · 100% evidence Valuation 10.3/20 · P/E 16.3× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 10.6% · 1 year -8.6% · 25% evidence · 12 of 12 weeks ahead Exact sum: 22.1 + 14.1 + 10.3 + 12.4 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · turning · Evidence leans up · 100% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.6/25 · ROCE 25.9% · Operating margin 23% · 100% evidence Valuation 9.2/20 · P/E 14.4× · PEG 2.27 · 100% evidence Relative strength 17.4/20 · Lead over its industry 7.1% · Lead over NIFTY 500 -2.8% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.8 + 19.6 + 9.2 + 17.4 = 57 · What this means: Relative strength against the index is -2.8%, and revenue and profit growth are weak. 9. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Evidence leans up · 93% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.6/25 · ROCE 11.4% · Operating margin 15% · 100% evidence Valuation 6.7/20 · P/E 24.7× · PEG 2.26 · 65% evidence Relative strength 8.4/20 · Lead over its industry -2.6% · Lead over NIFTY 500 -11.7% · 1 year -19.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 13.6 + 6.7 + 8.4 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · breaking out · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue -7.8% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 9.5/25 · ROCE 6.7% · Operating margin 18% · 100% evidence Valuation 9.6/20 · P/E 20.8× · PEG n/a · 15% evidence Relative strength 11.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.5% · 1 year -35% · 25% evidence · 11 of 12 weeks ahead Exact sum: 22 + 9.5 + 9.6 + 11 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Too little evidence to rank firmly · 59% evidence 51.0 out of 100 Growth Capital Valuation Relative
12. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative
13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 48.4 out of 100 Growth Capital Valuation Relative
14. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · quiet · Evidence leans down · 96% evidence 45.3 out of 100 Growth Capital Valuation Relative
15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 96% evidence 44.7 out of 100 Growth Capital Valuation Relative
16. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · Evidence leans down · 63% evidence 43.9 out of 100 Growth Capital Valuation Relative
17. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · quiet · Evidence leans down · 64% evidence 42.7 out of 100 Growth Capital Valuation Relative
18. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Evidence leans down · 96% evidence 42.0 out of 100 Growth Capital Valuation Relative
19. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans down · 90% evidence 42.0 out of 100 Growth Capital Valuation Relative
20. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 41.7 out of 100 Growth Capital Valuation Relative
21. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 71% evidence 41.5 out of 100 Growth Capital Valuation Relative
22. Insecticides India Ltd this page INSECTICID · quiet · Evidence leans down · 96% evidence 40.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.2/35 · Revenue 1.3% · Profit -16.7% · Operating margin change -1 points · 88% evidence Capital efficiency 12.5/25 · ROCE 15.8% · Operating margin 11% · 100% evidence Valuation 10.6/20 · P/E 12.1× · PEG 1.58 · 100% evidence Relative strength 8.2/20 · Lead over its industry -7.1% · Lead over NIFTY 500 -15.8% · 1 year -28.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9.2 + 12.5 + 10.6 + 8.2 = 40.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 23. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Evidence leans down · 81% evidence 38.3 out of 100 Growth Capital Valuation Relative
24. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 32.7 out of 100 Growth Capital Valuation Relative
25. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 76% evidence 29.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Insecticides India in size? Insecticides India is the 15th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: GSP Crop Science, Titan Biotech and Bharat Rasayan. Just below it: Meghmani Organics, India Pesticides and Astec Lifesciences. ### Pesticides/Agrochemicals companies close in size

1. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) ₹2,014 crore
2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) ₹1,755 crore
3. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) ₹1,557 crore
4. Insecticides India Ltd ₹1,511 crore
5. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) ₹1,339 crore
6. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) ₹1,297 crore
7. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ₹1,216 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [Frontier Springs Ltd](https://www.sectoralpha.in/stocks/frontier-springs-ltd) ₹1,513 crore · Railways - Kavach/Springs
2. [Jai Corp Ltd](https://www.sectoralpha.in/stocks/jai-corp-ltd) ₹1,512 crore · Miscellaneous
3. Insecticides India Ltd ₹1,511 crore
4. [Arfin India Ltd](https://www.sectoralpha.in/stocks/arfin-india-ltd) ₹1,510 crore · Aluminium Products
5. [PTC India Financial Services Ltd](https://www.sectoralpha.in/stocks/ptc-india-financial-services-ltd) ₹1,510 crore · Finance & Investments - Others

## What else do people ask about Insecticides India? ### What is Insecticides India's share price today? Insecticides India Ltd's share price is ₹555.15, −23.1% over the past year. The whole company is worth ₹1,616 Cr on the market. In the last 52 weeks it traded between ₹519 to ₹749; today it is 16% of the way up from the low, 13.4% below its 200-day average (as of 3 November 2026). ### What were Insecticides India's latest quarterly results? Insecticides India Ltd reported revenue of ₹612 Cr and net profit of ₹44.0 Cr for the Jun 2026 quarter. Revenue fell 11.4% and profit fell 24.1% compared with a year earlier. Earnings per share were ₹15.08. The operating margin was 11.0%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Insecticides India's market cap? Insecticides India Ltd's market capitalisation is ₹1,616 Cr at a share price of ₹555.15. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Insecticides India performing? Insecticides India Ltd's share price has been falling for 14 weeks. In its latest quarter, revenue fell 11.4% and profit fell 24.1% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 22 weeks running (as of 3 November 2026). ### Will Insecticides India's share price go up? This page does not forecast Insecticides India Ltd's share price. What it shows instead: the share price is ₹555.15, and it has been falling for 14 weeks. Its P/E of 12.9× is higher than 28% of its own last 10 years (as of 3 November 2026). ### Who owns Insecticides India? Promoters own 72.3% of Insecticides India Ltd, foreign institutions 4.4%, domestic institutions 9.3% and the public 14.0% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 1.0 percentage points over 8 quarters (as of 3 November 2026). ### Where is Insecticides India in its business cycle? Insecticides India Ltd's FY26 operating margin was 11.0%, against a 13-year range of 7.0% to 16.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Insecticides India story? The main question: the P/E is near the low end of its own history, higher than only 28% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Insecticides India a stock worth studying right now? What the numbers show: Insecticides India Ltd's P/E is near the low end of its own history, higher than only 28% of past readings, and its quarterly results are still getting worse. The main open question: whether results start to improve. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Insecticides India share price forecast for 2026? What management itself guided: Q2 expected positive on a year earlier and H2 expected to recover first-half industry losses. ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india

This is research, not advice. We’re not SEBI-registered.